Logo image of ERF.PA

EUROFINS SCIENTIFIC (ERF.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ERF - FR0014000MR3 - Common Stock

57.02 EUR
+0.28 (+0.49%)
Last: 12/10/2025, 12:24:02 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ERF. ERF was compared to 20 industry peers in the Life Sciences Tools & Services industry. ERF has an average financial health and profitability rating. ERF is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, ERF could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

ERF had positive earnings in the past year.
ERF had a positive operating cash flow in the past year.
Each year in the past 5 years ERF has been profitable.
Each year in the past 5 years ERF had a positive operating cash flow.
ERF.PA Yearly Net Income VS EBIT VS OCF VS FCFERF.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

ERF has a Return On Assets (3.54%) which is comparable to the rest of the industry.
ERF has a Return On Equity of 8.09%. This is comparable to the rest of the industry: ERF outperforms 60.00% of its industry peers.
ERF has a Return On Invested Capital of 9.79%. This is in the better half of the industry: ERF outperforms 80.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ERF is in line with the industry average of 9.25%.
The last Return On Invested Capital (9.79%) for ERF is above the 3 year average (8.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.54%
ROE 8.09%
ROIC 9.79%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ERF.PA Yearly ROA, ROE, ROICERF.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ERF has a worse Profit Margin (5.44%) than 60.00% of its industry peers.
In the last couple of years the Profit Margin of ERF has grown nicely.
With a Operating Margin value of 15.59%, ERF perfoms like the industry average, outperforming 55.00% of the companies in the same industry.
ERF's Operating Margin has improved in the last couple of years.
ERF has a Gross Margin of 23.29%. This is amonst the worse of the industry: ERF underperforms 80.00% of its industry peers.
ERF's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 15.59%
PM (TTM) 5.44%
GM 23.29%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
ERF.PA Yearly Profit, Operating, Gross MarginsERF.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ERF is creating some value.
Compared to 1 year ago, ERF has less shares outstanding
The number of shares outstanding for ERF has been increased compared to 5 years ago.
ERF has a better debt/assets ratio than last year.
ERF.PA Yearly Shares OutstandingERF.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ERF.PA Yearly Total Debt VS Total AssetsERF.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

An Altman-Z score of 2.60 indicates that ERF is not a great score, but indicates only limited risk for bankruptcy at the moment.
ERF's Altman-Z score of 2.60 is in line compared to the rest of the industry. ERF outperforms 50.00% of its industry peers.
The Debt to FCF ratio of ERF is 5.25, which is a neutral value as it means it would take ERF, 5.25 years of fcf income to pay off all of its debts.
ERF has a better Debt to FCF ratio (5.25) than 70.00% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that ERF is somewhat dependend on debt financing.
ERF's Debt to Equity ratio of 0.77 is on the low side compared to the rest of the industry. ERF is outperformed by 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.25
Altman-Z 2.6
ROIC/WACC1.21
WACC8.07%
ERF.PA Yearly LT Debt VS Equity VS FCFERF.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

ERF has a Current Ratio of 1.26. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.26, ERF is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 1.19 indicates that ERF should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.19, ERF belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.19
ERF.PA Yearly Current Assets VS Current LiabilitesERF.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.50% over the past year.
Measured over the past years, ERF shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.34% on average per year.
Looking at the last year, ERF shows a small growth in Revenue. The Revenue has grown by 2.53% in the last year.
ERF shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.78% yearly.
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%

3.2 Future

ERF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.60% yearly.
ERF is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.38% yearly.
EPS Next Y14.43%
EPS Next 2Y13.37%
EPS Next 3Y13.84%
EPS Next 5Y15.6%
Revenue Next Year5.07%
Revenue Next 2Y5.39%
Revenue Next 3Y5.87%
Revenue Next 5Y7.38%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ERF.PA Yearly Revenue VS EstimatesERF.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B 10B
ERF.PA Yearly EPS VS EstimatesERF.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

7

4. Valuation

4.1 Price/Earnings Ratio

ERF is valuated correctly with a Price/Earnings ratio of 15.84.
Based on the Price/Earnings ratio, ERF is valued cheaper than 90.00% of the companies in the same industry.
ERF is valuated rather cheaply when we compare the Price/Earnings ratio to 26.28, which is the current average of the S&P500 Index.
ERF is valuated correctly with a Price/Forward Earnings ratio of 14.36.
Based on the Price/Forward Earnings ratio, ERF is valued cheaper than 85.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ERF to the average of the S&P500 Index (23.52), we can say ERF is valued slightly cheaper.
Industry RankSector Rank
PE 15.84
Fwd PE 14.36
ERF.PA Price Earnings VS Forward Price EarningsERF.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ERF is valued cheaper than 90.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ERF is valued cheaply inside the industry as 95.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.25
EV/EBITDA 8.06
ERF.PA Per share dataERF.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ERF's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ERF has a very decent profitability rating, which may justify a higher PE ratio.
ERF's earnings are expected to grow with 13.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.1
PEG (5Y)0.86
EPS Next 2Y13.37%
EPS Next 3Y13.84%

4

5. Dividend

5.1 Amount

ERF has a Yearly Dividend Yield of 1.02%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 0.71, ERF pays a better dividend. On top of this ERF pays more dividend than 85.00% of the companies listed in the same industry.
With a Dividend Yield of 1.02, ERF pays less dividend than the S&P500 average, which is at 2.31.
Industry RankSector Rank
Dividend Yield 1.02%

5.2 History

On average, the dividend of ERF grows each year by 16.51%, which is quite nice.
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
ERF.PA Yearly Dividends per shareERF.PA Yearly Dividends per shareYearly Dividends per share 2018 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

54.91% of the earnings are spent on dividend by ERF. This is a bit on the high side, but may be sustainable.
The dividend of ERF is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP54.91%
EPS Next 2Y13.37%
EPS Next 3Y13.84%
ERF.PA Yearly Income VS Free CF VS DividendERF.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
ERF.PA Dividend Payout.ERF.PA Dividend Payout, showing the Payout Ratio.ERF.PA Dividend Payout.PayoutRetained Earnings

EUROFINS SCIENTIFIC

EPA:ERF (12/10/2025, 12:24:02 PM)

57.02

+0.28 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-21 2025-10-21
Earnings (Next)01-28 2026-01-28/amc
Inst Owners36.14%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap10.39B
Revenue(TTM)6.89B
Net Income(TTM)374.80M
Analysts69.47
Price Target65.73 (15.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.02%
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP54.91%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.46%
PT rev (3m)1.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.19%
EPS NY rev (3m)0.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE 15.84
Fwd PE 14.36
P/S 1.51
P/FCF 13.25
P/OCF 7.9
P/B 2.24
P/tB N/A
EV/EBITDA 8.06
EPS(TTM)3.6
EY6.31%
EPS(NY)3.97
Fwd EY6.96%
FCF(TTM)4.3
FCFY7.55%
OCF(TTM)7.22
OCFY12.66%
SpS37.84
BVpS25.45
TBVpS-3.69
PEG (NY)1.1
PEG (5Y)0.86
Graham Number45.4
Profitability
Industry RankSector Rank
ROA 3.54%
ROE 8.09%
ROCE 12.64%
ROIC 9.79%
ROICexc 10.74%
ROICexgc 34.1%
OM 15.59%
PM (TTM) 5.44%
GM 23.29%
FCFM 11.37%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexgc growth 3Y-18.17%
ROICexgc growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score7
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.25
Debt/EBITDA 2.1
Cap/Depr 84.94%
Cap/Sales 7.7%
Interest Coverage 9.93
Cash Conversion 77.37%
Profit Quality 209.21%
Current Ratio 1.26
Quick Ratio 1.19
Altman-Z 2.6
F-Score7
WACC8.07%
ROIC/WACC1.21
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
EPS Next Y14.43%
EPS Next 2Y13.37%
EPS Next 3Y13.84%
EPS Next 5Y15.6%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
Revenue Next Year5.07%
Revenue Next 2Y5.39%
Revenue Next 3Y5.87%
Revenue Next 5Y7.38%
EBIT growth 1Y14.03%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year83.84%
EBIT Next 3Y29.85%
EBIT Next 5Y22.43%
FCF growth 1Y113.13%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y31.31%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%

EUROFINS SCIENTIFIC / ERF.PA FAQ

What is the ChartMill fundamental rating of EUROFINS SCIENTIFIC (ERF.PA) stock?

ChartMill assigns a fundamental rating of 6 / 10 to ERF.PA.


Can you provide the valuation status for EUROFINS SCIENTIFIC?

ChartMill assigns a valuation rating of 7 / 10 to EUROFINS SCIENTIFIC (ERF.PA). This can be considered as Undervalued.


Can you provide the profitability details for EUROFINS SCIENTIFIC?

EUROFINS SCIENTIFIC (ERF.PA) has a profitability rating of 6 / 10.


How financially healthy is EUROFINS SCIENTIFIC?

The financial health rating of EUROFINS SCIENTIFIC (ERF.PA) is 5 / 10.


Is the dividend of EUROFINS SCIENTIFIC sustainable?

The dividend rating of EUROFINS SCIENTIFIC (ERF.PA) is 4 / 10 and the dividend payout ratio is 54.91%.